Loading…

Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective

Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospec...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2024-09, Vol.14, p.1434397
Main Authors: Bessems, Laura, Chen, Baixing, Uyttebroek, Saartje, Devolder, David, Lood, Cédric, Verwimp, Stefaan, De Munter, Paul, Debaveye, Yves, Depypere, Melissa, Spriet, Isabel, Van Gerven, Laura, Dupont, Lieven, Wagemans, Jeroen, van Noort, Vera, Lavigne, Rob, Metsemakers, Willem-Jan, Onsea, Jolien
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53
container_end_page
container_issue
container_start_page 1434397
container_title Frontiers in cellular and infection microbiology
container_volume 14
creator Bessems, Laura
Chen, Baixing
Uyttebroek, Saartje
Devolder, David
Lood, Cédric
Verwimp, Stefaan
De Munter, Paul
Debaveye, Yves
Depypere, Melissa
Spriet, Isabel
Van Gerven, Laura
Dupont, Lieven
Wagemans, Jeroen
van Noort, Vera
Lavigne, Rob
Metsemakers, Willem-Jan
Onsea, Jolien
description Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.
doi_str_mv 10.3389/fcimb.2024.1434397
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9f03b4647a604f80a39d76426b68fb15</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9f03b4647a604f80a39d76426b68fb15</doaj_id><sourcerecordid>3106462824</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53</originalsourceid><addsrcrecordid>eNpVksFu1DAQhiMEolXpC3BAPnLJ4tiOY3NBqKKlUqVe4GyNnfGuSxIH21tUnp6ku1TtXDwa__PNyP6r6n1DN5wr_cm7MNoNo0xsGsEF192r6pQx3tZMK_X6WX5Sned8R5foKFOav61OuGaa6q47rf7cziWM4S-UECcSPbHgCqYQ5x1skZQdJpgfiI-J9MH74PZDqUusS0IoZNznpRDzLxywwEDC5NGtpPyZALE4ud0qttjn0COZMeV5Fdzju-qNhyHj-fE8q35efvtx8b2-ub26vvh6Uzve0lJD27fMe8uA2l43yiupKdeadyBb2gkHjtOu75htfC-V9Z2Qy2N4CdhwBS0_q64P3D7CnZlTGCE9mAjBPBZi2hpIJbgBjfaUWyHFgqbCKwpc950UTFqpvG1W1pcDa97bEXuHU0kwvIC-vJnCzmzjvWkaQVtO6UL4eCSk-HuPuZgxZIfDABPGfTa8oVJIpphYpOwgdSnmnNA_zWmoWR1gHh1gVgeYowOWpg_PN3xq-f_f_B-X4LAm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106462824</pqid></control><display><type>article</type><title>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</title><source>PubMed (Medline)</source><creator>Bessems, Laura ; Chen, Baixing ; Uyttebroek, Saartje ; Devolder, David ; Lood, Cédric ; Verwimp, Stefaan ; De Munter, Paul ; Debaveye, Yves ; Depypere, Melissa ; Spriet, Isabel ; Van Gerven, Laura ; Dupont, Lieven ; Wagemans, Jeroen ; van Noort, Vera ; Lavigne, Rob ; Metsemakers, Willem-Jan ; Onsea, Jolien</creator><creatorcontrib>Bessems, Laura ; Chen, Baixing ; Uyttebroek, Saartje ; Devolder, David ; Lood, Cédric ; Verwimp, Stefaan ; De Munter, Paul ; Debaveye, Yves ; Depypere, Melissa ; Spriet, Isabel ; Van Gerven, Laura ; Dupont, Lieven ; Wagemans, Jeroen ; van Noort, Vera ; Lavigne, Rob ; Metsemakers, Willem-Jan ; Onsea, Jolien</creatorcontrib><description>Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.</description><identifier>ISSN: 2235-2988</identifier><identifier>EISSN: 2235-2988</identifier><identifier>DOI: 10.3389/fcimb.2024.1434397</identifier><identifier>PMID: 39290977</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Bacteria - virology ; Bacterial Infections - therapy ; bacteriophage therapy ; bacteriophages ; Bacteriophages - physiology ; bench-to-bedside ; Cellular and Infection Microbiology ; Humans ; Musculoskeletal Diseases - microbiology ; Musculoskeletal Diseases - therapy ; musculoskeletal infections ; Phage Therapy - methods ; Prospective Studies ; treatment optimization</subject><ispartof>Frontiers in cellular and infection microbiology, 2024-09, Vol.14, p.1434397</ispartof><rights>Copyright © 2024 Bessems, Chen, Uyttebroek, Devolder, Lood, Verwimp, De Munter, Debaveye, Depypere, Spriet, Van Gerven, Dupont, Wagemans, van Noort, Lavigne, Metsemakers and Onsea.</rights><rights>Copyright © 2024 Bessems, Chen, Uyttebroek, Devolder, Lood, Verwimp, De Munter, Debaveye, Depypere, Spriet, Van Gerven, Dupont, Wagemans, van Noort, Lavigne, Metsemakers and Onsea 2024 Bessems, Chen, Uyttebroek, Devolder, Lood, Verwimp, De Munter, Debaveye, Depypere, Spriet, Van Gerven, Dupont, Wagemans, van Noort, Lavigne, Metsemakers and Onsea</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405300/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405300/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39290977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bessems, Laura</creatorcontrib><creatorcontrib>Chen, Baixing</creatorcontrib><creatorcontrib>Uyttebroek, Saartje</creatorcontrib><creatorcontrib>Devolder, David</creatorcontrib><creatorcontrib>Lood, Cédric</creatorcontrib><creatorcontrib>Verwimp, Stefaan</creatorcontrib><creatorcontrib>De Munter, Paul</creatorcontrib><creatorcontrib>Debaveye, Yves</creatorcontrib><creatorcontrib>Depypere, Melissa</creatorcontrib><creatorcontrib>Spriet, Isabel</creatorcontrib><creatorcontrib>Van Gerven, Laura</creatorcontrib><creatorcontrib>Dupont, Lieven</creatorcontrib><creatorcontrib>Wagemans, Jeroen</creatorcontrib><creatorcontrib>van Noort, Vera</creatorcontrib><creatorcontrib>Lavigne, Rob</creatorcontrib><creatorcontrib>Metsemakers, Willem-Jan</creatorcontrib><creatorcontrib>Onsea, Jolien</creatorcontrib><title>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</title><title>Frontiers in cellular and infection microbiology</title><addtitle>Front Cell Infect Microbiol</addtitle><description>Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.</description><subject>Bacteria - virology</subject><subject>Bacterial Infections - therapy</subject><subject>bacteriophage therapy</subject><subject>bacteriophages</subject><subject>Bacteriophages - physiology</subject><subject>bench-to-bedside</subject><subject>Cellular and Infection Microbiology</subject><subject>Humans</subject><subject>Musculoskeletal Diseases - microbiology</subject><subject>Musculoskeletal Diseases - therapy</subject><subject>musculoskeletal infections</subject><subject>Phage Therapy - methods</subject><subject>Prospective Studies</subject><subject>treatment optimization</subject><issn>2235-2988</issn><issn>2235-2988</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksFu1DAQhiMEolXpC3BAPnLJ4tiOY3NBqKKlUqVe4GyNnfGuSxIH21tUnp6ku1TtXDwa__PNyP6r6n1DN5wr_cm7MNoNo0xsGsEF192r6pQx3tZMK_X6WX5Sned8R5foKFOav61OuGaa6q47rf7cziWM4S-UECcSPbHgCqYQ5x1skZQdJpgfiI-J9MH74PZDqUusS0IoZNznpRDzLxywwEDC5NGtpPyZALE4ud0qttjn0COZMeV5Fdzju-qNhyHj-fE8q35efvtx8b2-ub26vvh6Uzve0lJD27fMe8uA2l43yiupKdeadyBb2gkHjtOu75htfC-V9Z2Qy2N4CdhwBS0_q64P3D7CnZlTGCE9mAjBPBZi2hpIJbgBjfaUWyHFgqbCKwpc950UTFqpvG1W1pcDa97bEXuHU0kwvIC-vJnCzmzjvWkaQVtO6UL4eCSk-HuPuZgxZIfDABPGfTa8oVJIpphYpOwgdSnmnNA_zWmoWR1gHh1gVgeYowOWpg_PN3xq-f_f_B-X4LAm</recordid><startdate>20240903</startdate><enddate>20240903</enddate><creator>Bessems, Laura</creator><creator>Chen, Baixing</creator><creator>Uyttebroek, Saartje</creator><creator>Devolder, David</creator><creator>Lood, Cédric</creator><creator>Verwimp, Stefaan</creator><creator>De Munter, Paul</creator><creator>Debaveye, Yves</creator><creator>Depypere, Melissa</creator><creator>Spriet, Isabel</creator><creator>Van Gerven, Laura</creator><creator>Dupont, Lieven</creator><creator>Wagemans, Jeroen</creator><creator>van Noort, Vera</creator><creator>Lavigne, Rob</creator><creator>Metsemakers, Willem-Jan</creator><creator>Onsea, Jolien</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240903</creationdate><title>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</title><author>Bessems, Laura ; Chen, Baixing ; Uyttebroek, Saartje ; Devolder, David ; Lood, Cédric ; Verwimp, Stefaan ; De Munter, Paul ; Debaveye, Yves ; Depypere, Melissa ; Spriet, Isabel ; Van Gerven, Laura ; Dupont, Lieven ; Wagemans, Jeroen ; van Noort, Vera ; Lavigne, Rob ; Metsemakers, Willem-Jan ; Onsea, Jolien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bacteria - virology</topic><topic>Bacterial Infections - therapy</topic><topic>bacteriophage therapy</topic><topic>bacteriophages</topic><topic>Bacteriophages - physiology</topic><topic>bench-to-bedside</topic><topic>Cellular and Infection Microbiology</topic><topic>Humans</topic><topic>Musculoskeletal Diseases - microbiology</topic><topic>Musculoskeletal Diseases - therapy</topic><topic>musculoskeletal infections</topic><topic>Phage Therapy - methods</topic><topic>Prospective Studies</topic><topic>treatment optimization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bessems, Laura</creatorcontrib><creatorcontrib>Chen, Baixing</creatorcontrib><creatorcontrib>Uyttebroek, Saartje</creatorcontrib><creatorcontrib>Devolder, David</creatorcontrib><creatorcontrib>Lood, Cédric</creatorcontrib><creatorcontrib>Verwimp, Stefaan</creatorcontrib><creatorcontrib>De Munter, Paul</creatorcontrib><creatorcontrib>Debaveye, Yves</creatorcontrib><creatorcontrib>Depypere, Melissa</creatorcontrib><creatorcontrib>Spriet, Isabel</creatorcontrib><creatorcontrib>Van Gerven, Laura</creatorcontrib><creatorcontrib>Dupont, Lieven</creatorcontrib><creatorcontrib>Wagemans, Jeroen</creatorcontrib><creatorcontrib>van Noort, Vera</creatorcontrib><creatorcontrib>Lavigne, Rob</creatorcontrib><creatorcontrib>Metsemakers, Willem-Jan</creatorcontrib><creatorcontrib>Onsea, Jolien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in cellular and infection microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bessems, Laura</au><au>Chen, Baixing</au><au>Uyttebroek, Saartje</au><au>Devolder, David</au><au>Lood, Cédric</au><au>Verwimp, Stefaan</au><au>De Munter, Paul</au><au>Debaveye, Yves</au><au>Depypere, Melissa</au><au>Spriet, Isabel</au><au>Van Gerven, Laura</au><au>Dupont, Lieven</au><au>Wagemans, Jeroen</au><au>van Noort, Vera</au><au>Lavigne, Rob</au><au>Metsemakers, Willem-Jan</au><au>Onsea, Jolien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective</atitle><jtitle>Frontiers in cellular and infection microbiology</jtitle><addtitle>Front Cell Infect Microbiol</addtitle><date>2024-09-03</date><risdate>2024</risdate><volume>14</volume><spage>1434397</spage><pages>1434397-</pages><issn>2235-2988</issn><eissn>2235-2988</eissn><abstract>Given the increasing threat of antimicrobial resistance, scientists are urgently seeking adjunct antimicrobial strategies, such as phage therapy (PT). However, despite promising results for the treatment of musculoskeletal infections in our center, crucial knowledge gaps remain. Therefore, a prospective observational study (PHAGEFORCE) and a multidisciplinary approach was set up to achieve and optimize standardized treatment guidelines. At our center, PT is strictly controlled and monitored by a multidisciplinary taskforce. Each phage treatment follows the same pathway to ensure standardization and data quality. Within the PHAGEFORCE framework, we established a testing platform to gain insight in the safety and efficacy of PT, biodistribution, phage kinetics and the molecular interaction between phages and bacteria. The draining fluid is collected to determine the phage titer and bacterial load. In addition, all bacterial isolates are fully characterized by genome sequencing to monitor the emergence of phage resistance. We hereby present a standardized bench-to-bedside protocol to gain more insight in the kinetics and dynamics of PT for musculoskeletal infections.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39290977</pmid><doi>10.3389/fcimb.2024.1434397</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2235-2988
ispartof Frontiers in cellular and infection microbiology, 2024-09, Vol.14, p.1434397
issn 2235-2988
2235-2988
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9f03b4647a604f80a39d76426b68fb15
source PubMed (Medline)
subjects Bacteria - virology
Bacterial Infections - therapy
bacteriophage therapy
bacteriophages
Bacteriophages - physiology
bench-to-bedside
Cellular and Infection Microbiology
Humans
Musculoskeletal Diseases - microbiology
Musculoskeletal Diseases - therapy
musculoskeletal infections
Phage Therapy - methods
Prospective Studies
treatment optimization
title Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A43%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20bacteriophage%20therapy%20for%20difficult-to-treat%20musculoskeletal%20infections:%20a%20bench-to-bedside%20perspective&rft.jtitle=Frontiers%20in%20cellular%20and%20infection%20microbiology&rft.au=Bessems,%20Laura&rft.date=2024-09-03&rft.volume=14&rft.spage=1434397&rft.pages=1434397-&rft.issn=2235-2988&rft.eissn=2235-2988&rft_id=info:doi/10.3389/fcimb.2024.1434397&rft_dat=%3Cproquest_doaj_%3E3106462824%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-a5d52ffb2a0bd918f869039937a65074cac307d72b1fd68bf746343f6ae138a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3106462824&rft_id=info:pmid/39290977&rfr_iscdi=true